$SNDX
Syndax Pharmaceuticals Inc

2021 Q3 Form 10-Q Financial Statement

#000156459021057004 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3 2020 Q2
Revenue $12.38M $379.0K $379.0K
YoY Change 3165.17% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.801M $5.820M $6.050M
YoY Change 16.86% 61.22% 74.86%
% of Gross Profit
Research & Development $25.61M $14.41M $10.94M
YoY Change 77.72% 45.2% -10.96%
% of Gross Profit
Depreciation & Amortization $8.000K $20.00K $30.00K
YoY Change -60.0%
% of Gross Profit
Operating Expenses $32.41M $20.23M $16.99M
YoY Change 60.18% 49.56% 7.85%
Operating Profit -$20.03M -$19.85M -$16.61M
YoY Change 0.9% 50.98% 8.04%
Interest Expense -$566.0K -$460.0K $638.0K
YoY Change 23.04% -216.46% 27.35%
% of Operating Profit
Other Income/Expense, Net -$41.00K -$584.0K -$452.0K
YoY Change -92.98% -282.5% -198.69%
Pretax Income -$20.64M -$20.44M -$17.06M
YoY Change 0.97% 59.31% 14.34%
Income Tax
% Of Pretax Income
Net Earnings -$20.64M -$20.44M -$17.06M
YoY Change 0.99% 59.3% 14.39%
Net Earnings / Revenue -166.78% -5392.35% -4501.85%
Basic Earnings Per Share -$0.40
Diluted Earnings Per Share -$397.2K -$462.9K -$420.1K
COMMON SHARES
Basic Shares Outstanding 51.96M 38.55M
Diluted Shares Outstanding 51.96M

Balance Sheet

Concept 2021 Q3 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $236.2M $175.7M $189.7M
YoY Change 34.44% 140.68% 126.64%
Cash & Equivalents $71.43M $56.40M $53.73M
Short-Term Investments $164.8M $119.4M $136.1M
Other Short-Term Assets $1.857M $1.400M $1.900M
YoY Change 32.64% -12.5% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $238.3M $177.4M $191.8M
YoY Change 34.3% 137.01% 123.61%
LONG-TERM ASSETS
Property, Plant & Equipment $1.251M $600.0K $700.0K
YoY Change 108.5% 97.37% 114.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $1.300M $100.0K
YoY Change -100.0% 224.19% -50.25%
Total Long-Term Assets $1.251M $1.900M $800.0K
YoY Change -34.16% 24.1% -50.46%
TOTAL ASSETS
Total Short-Term Assets $238.3M $177.4M $191.8M
Total Long-Term Assets $1.251M $1.900M $800.0K
Total Assets $239.5M $179.3M $192.6M
YoY Change 33.58% 134.74% 120.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.122M $3.800M $1.800M
YoY Change 34.79% -43.76% -20.91%
Accrued Expenses $14.10M $9.800M $9.100M
YoY Change 43.89% -2.0% -33.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $9.489M
YoY Change
Total Short-Term Liabilities $28.71M $15.20M $12.50M
YoY Change 88.89% -16.91% -28.53%
LONG-TERM LIABILITIES
Long-Term Debt $10.99M $20.00M $19.90M
YoY Change -45.06%
Other Long-Term Liabilities $798.0K $12.20M $12.60M
YoY Change -93.46% 203233.33% 179900.0%
Total Long-Term Liabilities $11.79M $32.20M $32.50M
YoY Change -63.39% 129.28% 122.24%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.71M $15.20M $12.50M
Total Long-Term Liabilities $11.79M $32.20M $32.50M
Total Liabilities $40.50M $47.30M $45.00M
YoY Change -14.38% 46.27% 40.12%
SHAREHOLDERS EQUITY
Retained Earnings -$527.8M
YoY Change 12.62%
Common Stock $675.3M
YoY Change 28.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $199.0M $132.0M $147.6M
YoY Change
Total Liabilities & Shareholders Equity $239.5M $179.3M $192.6M
YoY Change 33.58% 134.74% 120.42%

Cashflow Statement

Concept 2021 Q3 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$20.64M -$20.44M -$17.06M
YoY Change 0.99% 59.3% 14.39%
Depreciation, Depletion And Amortization $8.000K $20.00K $30.00K
YoY Change -60.0%
Cash From Operating Activities -$24.94M -$18.30M -$21.40M
YoY Change 36.31% 114.54% 70.79%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $26.63M $19.28M -$78.62M
YoY Change 38.13% 55.86% 315.32%
Cash From Investing Activities $26.63M $19.28M -$78.62M
YoY Change 38.13% 55.86% 315.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $107.9M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.705M 1.770M 109.0M
YoY Change -3.67% 2112.5%
NET CHANGE
Cash From Operating Activities -24.94M -18.30M -21.40M
Cash From Investing Activities 26.63M 19.28M -78.62M
Cash From Financing Activities 1.705M 1.770M 109.0M
Net Change In Cash 3.392M 2.750M 8.980M
YoY Change 23.35% -29.85% -128.54%
FREE CASH FLOW
Cash From Operating Activities -$24.94M -$18.30M -$21.40M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
9489000
CY2020Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
17834000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47881223
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47881223
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-4000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-568628000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
252188000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
300613000
us-gaap Profit Loss
ProfitLoss
-71272000
sndx Depreciation And Related Adjustment
DepreciationAndRelatedAdjustment
33000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-473000
sndx Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
302000
us-gaap Paid In Kind Interest
PaidInKindInterest
358000
us-gaap Share Based Compensation
ShareBasedCompensation
9388000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20437000
us-gaap Net Income Loss
NetIncomeLoss
-71272000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-56641000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.38
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.43
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44156808
us-gaap Net Income Loss
NetIncomeLoss
-52735000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20437000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-71272000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
51690173
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39714490
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
2095039
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2021Q1 sndx Number Of Pre Funded Warrants Exchanged For Common Stock
NumberOfPreFundedWarrantsExchangedForCommonStock
250000
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2020Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
168269000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
14000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
168280000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
182823000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
182819000
CY2021Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
6499000
CY2020Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
4683000
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
1259000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
427000
CY2021Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
182000
CY2020Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
175000
CY2021Q3 sndx Prepaid Subscriptions
PrepaidSubscriptions
242000
CY2020Q4 sndx Prepaid Subscriptions
PrepaidSubscriptions
203000
CY2020Q4 us-gaap Supplies
Supplies
58000
CY2021Q3 sndx Reimbursable Costs
ReimbursableCosts
3000
CY2020Q4 sndx Reimbursable Costs
ReimbursableCosts
24000
CY2021Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
238000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
114000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8423000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5684000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7022000
CY2021Q3 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
9058000
CY2020Q4 sndx Accrued Clinical Costs Current
AccruedClinicalCostsCurrent
7132000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3468000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3213000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
854000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000
CY2021Q3 sndx Accrued Interest Payable
AccruedInterestPayable
164000
CY2020Q4 sndx Accrued Interest Payable
AccruedInterestPayable
170000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
188000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
358000
CY2021Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
13732000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11246000
CY2021Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
79000
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
9489000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
252188000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2767000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
881000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2021Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
64000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Expenses
StockIssuedDuringPeriodValueAtTheMarketOfferingExpenses
200000
CY2021Q2 sndx Stock Issued During Period Value At The Market Offering Net
StockIssuedDuringPeriodValueAtTheMarketOfferingNet
5131000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
825000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3381000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3063000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9388000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7022000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
414809
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3300000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
311871
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3100000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
2285000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
9727000
CY2021Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7988000
CY2021Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
20000000
CY2021Q3 sndx Amortized Losses Reacquired Debt Noncurrent
AmortizedLossesReacquiredDebtNoncurrent
589000
CY2021Q3 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
111000
CY2021Q3 us-gaap Loans Payable
LoansPayable
20478000
CY2021Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
99000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1606000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-20639000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
199004000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
338000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
31600000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1829000
CY2020Q1 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
93000
CY2020Q1 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
24201000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrant Offering Expenses
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantOfferingExpenses
41000
CY2020Q1 sndx Stock Issued During Period Value Pre Funded Common Stock Warrants From Direct Offering
StockIssuedDuringPeriodValuePreFundedCommonStockWarrantsFromDirectOffering
10665000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2020Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
64000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-15236000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
53509000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2130000
CY2020Q2 sndx Stock Issued During Period Value Offering Expenses
StockIssuedDuringPeriodValueOfferingExpenses
7099000
CY2020Q2 sndx Stock Issued During Period Value Direct Offering
StockIssuedDuringPeriodValueDirectOffering
107901000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1015000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
69000
CY2020Q2 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
85000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-17062000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
147647000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3063000
CY2020Q3 sndx Offering Expenses Associated With Direct Offering
OfferingExpensesAssociatedWithDirectOffering
33000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1707000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-64000
CY2020Q3 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
94000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-20437000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
131977000
CY2019Q1 sndx Number Of Series Of Warrants
NumberOfSeriesOfWarrants
2
CY2019Q1 sndx Gross Proceeds From Offering
GrossProceedsFromOffering
27600000
CY2019Q1 sndx Offering Cost
OfferingCost
200000
CY2019Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P1Y4M24D
CY2020Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
3036719
CY2020Q1 sndx Adjustments To Additional Paid In Capital Repricing Warrants
AdjustmentsToAdditionalPaidInCapitalRepricingWarrants
3900000
CY2020Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P0Y4M24D

Files In Submission

Name View Source Status
0001564590-21-057004-index-headers.html Edgar Link pending
0001564590-21-057004-index.html Edgar Link pending
0001564590-21-057004.txt Edgar Link pending
0001564590-21-057004-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sndx-10q_20210930.htm Edgar Link pending
sndx-10q_20210930_htm.xml Edgar Link completed
sndx-20210930.xsd Edgar Link pending
sndx-20210930_cal.xml Edgar Link unprocessable
sndx-20210930_def.xml Edgar Link unprocessable
sndx-20210930_lab.xml Edgar Link unprocessable
sndx-20210930_pre.xml Edgar Link unprocessable
sndx-ex101_182.htm Edgar Link pending
sndx-ex102_181.htm Edgar Link pending
sndx-ex311_8.htm Edgar Link pending
sndx-ex312_7.htm Edgar Link pending
sndx-ex321_6.htm Edgar Link pending